Cancer risk assessment tools in primary care: A systematic review of randomized controlled trials

Annals of Family Medicine

Volumn 13, Issue 5, 2015, Pages 480-489

  Walker, J G ^a   Licqurish, S ^a   Chiang, P ^a   Pirotta, M ^a   Emery, J D ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cancer screening; Practice based research; Primary care; Risk assessment tools

Indexed keywords

EARLY CANCER DIAGNOSIS; HEALTH PROMOTION; HUMAN; NEOPLASMS; ORGANIZATION AND MANAGEMENT; PATIENT SATISFACTION; PRIMARY HEALTH CARE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

EARLY DETECTION OF CANCER; HEALTH PROMOTION; HUMANS; NEOPLASMS; PATIENT SATISFACTION; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 84941359794     PISSN: 15441709     EISSN: 15441717     Source Type: Journal    
DOI: 10.1370/afm.1837     Document Type: Article

References (37)

1. Australian Government Department of Health. BreastScreen Australia. http://www.cancerscreening.gov.au/internet/screening/ publishing.nsf/Content/breast-screening-1. Accessed Aug 21, 2014.
2. Australian Government Department of Health. National Bowel Cancer Screening Program. http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/bowel-screening-1. Accessed Jul 27, 2014.
3. Australian Government Department of Health. National Cervical Screening Program. http://www.cancerscreening.gov.au/internet/ screening/publishing.nsf/Content/cervical-screening-1. Accessed Aug 21, 2014.
4. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855):1778-1786.
5. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31-41.
6. Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12(5):496-503.
7. Burton H, Chowdhury S, Dent T, Hall A, Pashayan N, Pharoah P. Public health implications from COGS and potential for risk stratification and screening. Nat Genet. 2013;45(4):349-351.
8. Marcus J, Page D, Watson P, Narod S, Lenoir G, Lynch H. BRCA1 and BRCA2 hereditary breast carcinoma phenotypes. Cancer. 1997;80(S3):543-556.
9. Aaltonen L, Johns L, Järvinen H, Mecklin J-P, Houlston R. Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clin Cancer Res. 2007;13(1):356-361.
10. Yarnall JM, Crouch DJ, Lewis CM. Incorporating non-genetic risk factors and behavioural modifications into risk prediction models for colorectal cancer. Cancer Epidemiol. 2013;37(3):324-329.
11. Khoury MJ, Gwinn ML, Glasgow RE, Kramer BS. A population approach to precision medicine. Am J Prev Med. 2012;42(6):639-645.
12. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Bodymass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-578.
13. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.
14. US Department of Health and Human Services. National Cancer Institute. Colorectal Cancer Risk Tool. http://www.cancer.gov/ colorectalcancerrisk/tool.aspx. Accessed Aug 21, 2014.
15. Freedman AN, Seminara D, Gail MH, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst. 2005;97(10):715-723.
16. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
17. Wang W, Niendorf KB, Patel D, et al. Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. Cancer Res. 2010;70(2):552-559.
18. Emery JD, Shaw K, Williams B, et al. The role of primary care in early detection and follow-up of cancer. Nat Rev Clin Oncol. 2014;11(1):38-48.
19. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269, W64.
20. Walker J, Pirotta M, Licqurish S, Chiang PP-C, Emery J. Systematic review of the clinical use of risk assessment tools in primary care for cancer screening. 2014. http://www.crd.york.ac.uk/PROSPERO. Accessed Dec 2, 2013.
21. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. London, England: The Cochrane Collaboration and John Wiley & Sons Ltd; 2008.
22. Schroy PC III, Emmons K, Peters E, et al. The impact of a novel computer-based decision aid on shared decision making for colorectal cancer screening: a randomized trial. Med Decis Making. 2011; 31(1):93-107.
23. Schroy PC III, Emmons KM, Peters E, et al. Aid-assisted decision making and colorectal cancer screening: a randomized controlled trial. Am J Prev Med. 2012;43(6):573-583.
24. Rubinstein WS, Acheson LS, O’Neill SM, et al; Family Healthware Impact Trial (FHITr) Group. Clinical utility of family history for cancer screening and referral in primary care: a report from the Family Healthware Impact Trial. Genet Med. 2011;13(11):956-965.
25. Ruffin MT IV, Nease DE Jr, Sen A, et al; Family History Impact Trial (FHITr) Group. Effect of preventive messages tailored to family history on health behaviors: the Family Healthware Impact Trial. Ann Fam Med. 2011;9(1):3-11.
26. Wang C, Sen A, Ruffin MT IV, et al; Family Healthware™ Impact Trial (FHITr) Group. Family history assessment: impact on disease risk perceptions. Am J Prev Med. 2012;43(4):392-398.
27. Emery J, Morris H, Goodchild R, et al. The GRAIDS Trial: a cluster randomised controlled trial of computer decision support for the management of familial cancer risk in primary care. Br J Cancer. 2007;97(4):486-493.
28. Campbell E, Peterkin D, Abbott R, Rogers J. Encouraging underscreened women to have cervical cancer screening: the effectiveness of a computer strategy. Prev Med. 1997;26(6):801-807.
29. Wilson BJ, Torrance N, Mollison J, et al. Cluster randomized trial of a multifaceted primary care decision-support intervention for inherited breast cancer risk. Fam Pract. 2006;23(5):537-544.
30. Emmons KM, Wong M, Puleo E, Weinstein N, Fletcher R, Colditz G. Tailored computer-based cancer risk communication: correcting colorectal cancer risk perception. J Health Commun. 2004; 9(2):127-141.
31. Weinstein ND, Atwood K, Puleo E, Fletcher R, Colditz G, Emmons K. Colon cancer: risk perceptions and risk communication. J Health Commun. 2004;9(1):53-65.
32. Holloway RM, Wilkinson C, Peters TJ, et al. Cluster-randomised trial of risk communication to enhance informed uptake of cervical screening. Br J Gen Pract. 2003;53(493):620-625.
33. Stacey D, Légaré F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;1:CD001431.
34. Edwards A, Unigwe S, Elwyn G, Hood K. Effects of communicating individual risks in screening programmes: Cochrane systematic review. BMJ. 2003;327(7417):703-709.
35. Spiegelhalter DJ. Understanding uncertainty. Ann Fam Med. 2008; 6(3):196-197.
36. Trevena LJ, Zikmund-Fisher BJ, Edwards A, et al. Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers. BMC Med Inform Decis Mak. 2013;13(Suppl 2):S7.
37. Ait Ouakrim D, Boussioutas A, Lockett T, et al. Screening practices of unaffected people at familial risk of colorectal cancer. Cancer Prev Res (Phila). 2012;5(2):240-247.